This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).
Plasma phosphorylated tau (p‐tau), particularly p‐tau217, is a highly specific biomarker of Alzheimer's disease (AD) pathology. However, plasma p‐tau217 can be elevated in rare non‐AD conditions. Brain‐derived (BD) p‐tau217 may reduce these off‐target effects, but its performance against neuropathology has not been eva...
Marisa N. Denkinger, W. Brum, A. Leuzy et al.· Alzheimer's & Dementia· 0 citations
There is a need for early, objective markers of Alzheimer's disease (AD)‐related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β‐synuclein is elevated in the blood of adults with DS. This study evaluates the positioning of these changes relative to changes in pathophysiological blood bi...
Alba Cervantes González, A. Morcillo-Nieto, Sara Serrano et al.· Alzheimer's & Dementia· 0 citations
The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...
W. Omori, N. Kajitani, M. Okada-Tsuchioka et al.· Neuropsychopharmacology Repo...· 0 citations
Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.
Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al.· Alzheimer's & Dementia· 0 citations
Mounting evidence suggests beta amyloid (Aβ) is not the sole initiating driver of cognitive decline in Alzheimer's disease (AD). This study explores whether there is an association between cognitive decline over eight years and Aβ.
Joshua David, Isabella Torres, Evan Smith et al.· Brain and Behavior· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
